TAK-925 Placebo

DRUG2 trials

Sponsors

Takeda, Millennium Pharmaceuticals, Inc.

Conditions

Healthy VolunteersIdiopathic Hypersomnia

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

CompletedNCT03522506

TakedaHealthy Volunteers

Start: 2018-05-09End: 2018-11-07Updated: 2021-03-26

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

CompletedNCT04091438

Millennium Pharmaceuticals, Inc.Idiopathic Hypersomnia

Start: 2020-01-26End: 2020-11-23Updated: 2023-09-26

Related Papers

Orexin 2 receptor‐selective agonist danavorexton (<scp>TAK</scp>‐925) promotes wakefulness in non‐human primates and healthy individuals

Journal of Sleep Research2023-03-1926 citations

Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia

SLEEP2023-03-0812 citations

Safety and pharmacodynamics of a single infusion of TAK-925 in adults with idiopathic hypersomnia (S1.009)

Neurology2022-05-03